Some thyroid cancer patients classified as low or intermediate risk by standard guidelines actually had hidden cancer cells that were only visible on radioactive iodine scans, meaning current risk models may overlook disease that could be treated with radioactive iodine.
Evidence from Studies
No evidence studies found yet.
What Would Prove This
Per GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this claim, ordered from strongest to weakest.
Whether disease status stratification detects more occult disease than ATA risk stratification across multiple studies in patients with low-intermediate risk thyroid cancer.
A systematic review and meta-analysis of all prospective studies comparing detection rates of occult disease (via Tgoff + imaging) versus ATA risk stratification in patients classified as low-intermediate risk, with primary outcome of occult disease detection rate and secondary outcomes of subsequent recurrence.
Whether using disease status stratification to guide radioiodine therapy reduces recurrence rates compared to ATA risk stratification in patients with low-intermediate risk thyroid cancer.
A multicenter, double-blind RCT of 600 patients with low-intermediate risk DTC, randomized to receive radioiodine therapy guided by disease status (Tgoff + imaging) or by ATA risk stratification, with primary endpoint of 5-year recurrence rate and mandatory imaging and Tg monitoring.
Whether patients classified as low-intermediate risk by ATA criteria but identified as having occult disease by disease status stratification have higher recurrence rates than those without occult disease.
A prospective cohort study of 1000 patients with low-intermediate risk DTC, where both ATA risk and disease status stratification are performed, and patients are followed for 7 years to compare recurrence rates between those with and without occult disease detected by imaging.
Whether patients who later developed recurrence were more likely to have been classified as low-intermediate risk by ATA criteria but had occult disease on imaging.
A case-control study comparing 120 patients with recurrence after initial low-intermediate risk classification to 240 matched controls without recurrence, assessing whether they had occult disease detected by Tgoff and imaging at initial staging.
The proportion of patients classified as low-intermediate risk by ATA criteria who have occult disease detected by radioiodine imaging at initial staging.
A cross-sectional analysis of 500 patients with low-intermediate risk DTC, performing Tgoff and radioiodine imaging at initial staging to determine the proportion with occult disease not predicted by ATA criteria.